Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of DNA prime followed by recombinant Tiantan vaccinia HIV vaccine boosts at different intervals
ChiCTR1900021422Phase 2Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Feb 2019
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of recombinant Tiantan vaccinia HIV vaccine in human immunodeficiency virus infection (HIV), sponsored by Beijing YouAn Hospital. Primary endpoints: Safety indexes, HIV antigen-specific antibody and 1 more. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
recombinant Tiantan vaccinia HIV vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR1900021422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021422.